NanoViricides (NNVC) 10-Q 14 Nov 18 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2018	Nov. 14, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q1
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		69,383,000
Entity Emerging Growth Company	false
Entity Small Business	false

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2018	Jun. 30, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 6,082,365	$ 7,081,771
Prepaid expenses	201,532	240,257
Total Current Assets	6,283,897	7,322,028
PROPERTY AND EQUIPMENT
Property and equipment	14,055,637	14,018,383
Accumulated depreciation	(3,348,610)	(3,177,290)
Property and equipment, net	10,707,027	10,841,093
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(86,094)	(84,025)
Trademark and patents, net	372,860	374,929
OTHER ASSETS
Security deposits	3,515	3,515
Service agreements	3,222	4,647
Other Assets	6,737	8,162
Total Assets	17,370,521	18,546,212
CURRENT LIABILITIES:
Accounts payable	320,097	223,339
Accounts payable – related party	718,457	107,468
Accrued expenses	231,175	253,049
Total Current Liabilities	1,392,270	881,948
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 69,382,560 and 69,171,740 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively	69,383	69,172
Additional paid-in capital	101,437,413	101,282,707
Accumulated deficit	(85,533,609)	(83,692,146)
Total Stockholders' Equity	15,978,251	17,664,264
Total Liabilities and Stockholders' Equity	17,370,521	18,546,212
Warrant [Member]
CURRENT LIABILITIES:
Derivative liability - warrants	122,541	298,092
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 5,064,110 and 4,531,394 shares issued and outstanding, at September 30, 2018 and June 30, 2018, respectively	$ 5,064	$ 4,531

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Sep. 30, 2018	Jun. 30, 2018
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	69,382,560	69,171,740
Common stock, shares, outstanding	69,382,560	69,171,740
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	8,500,000	8,500,000
Preferred stock, shares issued	5,064,110	4,531,394
Preferred stock, shares outstanding	5,064,110	4,531,394

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
OPERATING EXPENSES
Research and development	$ 1,411,483	$ 1,451,906
General and administrative	627,615	778,540
Total operating expenses	2,039,098	2,230,446
LOSS FROM OPERATIONS	(2,039,098)	(2,230,446)
OTHER INCOME (EXPENSE):
Interest income	22,084	24,394
Interest expense	0	(125,000)
Discount on convertible debentures	0	(239,351)
Change in fair value of derivatives	175,551	564,848
Other income, net	197,635	224,891
LOSS BEFORE INCOME TAXES	(1,841,463)	(2,005,555)
INCOME TAX PROVISION	0	0
NET LOSS	$ (1,841,463)	$ (2,005,555)
Net loss per common share – basic and diluted	$ (0.03)	$ (0.03)
Weighted average common shares outstanding – basic and diluted	69,185,965	63,307,083

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - 3 months ended Sep. 30, 2018 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Jun. 30, 2018	$ 17,664,264	$ 4,531	$ 69,172	$ 101,282,707	$ (83,692,146)
Balance (in shares) at Jun. 30, 2018		4,531,394	69,171,740
Series A Preferred stock issued for employee stock compensation	55,027	$ 533	$ 0	54,494	0
Series A Preferred stock issued for employee stock compensation (in shares)		532,716	0
Common stock issued for consulting and legal services rendered	79,460	$ 0	$ 192	79,268	0
Common stock issued for consulting and legal services rendered (in shares)		0	191,510
Stock options issued for compensation	11,920	$ 0	$ 0	11,920	0
Warrants issued to Scientific Advisory Board	1,543	0	0	1,543	0
Common shares issued for Directors fees	7,500	$ 0	$ 19	7,481	0
Common shares issued for Directors fees (in shares)		0	19,310
Net loss	(1,841,463)	$ 0	$ 0	0	(1,841,463)
Balance at Sep. 30, 2018	$ 15,978,251	$ 5,064	$ 69,383	$ 101,437,413	$ (85,533,609)
Balance (in shares) at Sep. 30, 2018		5,064,110	69,382,560

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,841,463)	$ (2,005,555)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	55,027	158,799
Common shares issued as compensation and for services	86,960	38,250
Warrants granted to Scientific Advisory Board	1,543	5,773
Stock-based compensation expense	11,920	0
Depreciation	171,320	166,189
Amortization	2,069	2,068
Change in fair value of derivative liability	(175,551)	(564,848)
Amortization of debt discount on convertible debenture	0	239,351
Changes in operating assets and liabilities:
Prepaid expenses	38,725	(2,254)
Other assets	1,425	14,257
Accounts payable	96,758	(45,427)
Accounts payable - related party	610,989	478,088
Accrued expenses	(21,874)	188
Deferred interest payable	0	(41,667)
NET CASH USED IN OPERATING ACTIVITIES	(962,152)	(1,556,788)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(37,254)	(30,433)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(999,406)	(1,587,221)
Cash and cash equivalents at beginning of period	7,081,771	15,099,461
Cash and cash equivalents at end of period	6,082,365	13,512,240
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$ 0	$ 166,667

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business NanoViricides, Inc. (the Company”) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. We are a company with several drugs in various stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide™ program alone, we have drug candidates against at least five indications at different stages of development. Of these, our shingles drug candidate is expected to enter human clinical trials in the very near future. It is in advanced, IND-enabling pre-clinical studies at present, and large-scale production is being performed to supply the safety-toxicology study. In addition, our drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). Chicken pox is re-emerging as a major disease especially in European countries, with 23,500 confirmed cases in the first six months of 2018. In addition, we have drugs in development against all influenzas in our FluCide™ program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have broad, exclusive licenses in perpetuity. The first license agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. In addition, the Company is negotiating a license for VZV (shingles, chicken pox virus), and the remaining human herpesviruses from TheraCour. For this purpose, the Company has conducted a valuation for the shingles and PHN indications. The negotiation process has begun in earnest, with Dr. Irach Taraporewala being appointed as the new Chief Executive Officer of the Company, effective September 1, 2018. To date, TheraCour has not withheld any licenses for antiviral nanomedicines that NanoViricides has asked for, and we anticipate that the licenses to the remaining herpes viruses including VZV will be executed once the due diligence process is completed.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Summary of Significant Accounting Policies Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 13, 2018. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018. Reclassifications and Prior Year Adjustments Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified $296,678 of expenses related to the Company’s laboratory facilities out of general and administrative expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact on the reported results of operations and net loss reported for the three months ended September 30, 2017. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2018 September 30, 2017 Options and Warrants 4,412,039 6,685,292 Total potentially outstanding dilutive common shares 4,412,039 6,685,292 At September 30, 2017, the number of potentially dilutive shares of the Company’s common stock into which the Series C debenture could be converted based upon the conversion provisions contained in the debenture was 952,381. The Series C debenture was redeemed for common stock effective November 13, 2017. The Company has also issued 5,064,110 shares of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company’s intellectual property. In the absence of a Change of Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control. The following represents the basic and diluted per share calculations for loss from continuing operations: For the three months ended 2018 2017 Calculation of basic and diluted loss per share of common stock: Net loss attributable to common stockholders $ (1,841,463 ) $ (2,005,555 ) Denominator for basic and diluted weighted average shares of common stock 69,185,965 63,307,083 Basic and diluted loss per share of common stock $ (0.03 ) $ (0.03 ) The Series C debenture was redeemed for Common Stock effective November 13, 2017. See Note 7. The Series C debenture was excluded from the loss per share calculation for the three-month period ended September 30, 2017 because the impact is anti-dilutive. Recently Issued Accounting Pronouncements In August 2018, the SEC issued the final rule on Disclosures About Changes in Stockholder’s Equity For filings on Form 10-Q, which extends to interim periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders’ equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders’ equity, in the form of reconciliation, for “the current and comparative year-to-date [interim] periods, with subtotals for each interim period,” i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the disclosure of changes in stockholders’ equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. The staff of the SEC has indicated it would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending December 31, 2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and disclosures. In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact on its financial statements. In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial statements.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3 - Liquidity and Going Concern The Company’s financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Company has an accumulated deficit at September 30, 2018 of approximately $85.5 million and a net loss of approximately $1.8 million and net cash used in operating activities of approximately $1 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2018, the Company had available cash and cash equivalents of approximately $6.1 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management adjusted its planned expenditures, activities, and programs, in accordance with budgetary constraints and in accordance with its expectations of obtaining additional financing. The Company has made several adjustments to its past expenditures in the ensuing annual budget, eliminating several expenses including a reduction in workforce and consultants to the extent feasible without affecting its program of drug development. In addition, the Company has focused its efforts primarily on a single lead program to minimize cost outlays, namely taking the shingles drug candidate against VZV into human clinical trials. Management’s budget indicates that these changes have freed up sufficient funds to allow for the ensuing costs of the external advanced IND-enabling studies of this drug candidate. Management has considered several options for obtaining additional funds that will be needed for future human clinical trials and to obtain the additional license from TheraCour for VZV and the remaining human herpes viruses. The Company is also evaluating the possibility of obtaining a mortgage on its fully owned cGMP-capable laboratory facility in Shelton, CT, in order to free up a portion of the fixed capital for usage as liquid working capital. In addition, the Company believes that it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these milestones, the Company would experience substantial improvement in the liquidity of the Company’s stock, and would significantly improve the Company’s ability to raise funds on the public markets at terms that may be substantially superior to the terms we are offered at present. Management believes that as a result of the management plan, the Company’s existing resources and access to the capital markets will be sufficient to fund the Company’s planned operations and expenditures through November 2019. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The accompanying unaudited financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, significant stockholder and Director Irach Taraporewala Chief Executive Officer TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder Milton Boniuk, MD Significant stockholder As of September 30, 2018 June 30, 2018 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month’ s invoice to be applied as a prepayment towards expenses. $ 718,457 $ 107,468 For the three months ended September 30, September 30, Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018. $ 846,688 $ 847,093 Debenture Interest Payable to a Director Coupon interest expense on the $5,000,000 Series C Debenture paid to Dr. Milton Boniuk for the three months ended September 30, 2017 was $125,000. The Series C debenture was redeemed for Common Stock effective November 13, 2017. See Note 7.

Property and Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property and Equipment Property and equipment, stated at cost, less accumulated depreciation consisted of the following: September 30, 2018 June 30, 2018 GMP Facility $ 8,020,471 $ 8,011,230 Land 260,000 260,000 Office Equipment 57,781 57,781 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,711,778 5,683,765 Total Property and Equipment 14,055,637 14,018,383 Less Accumulated Depreciation (3,348,610 ) (3,177,290 ) Property and Equipment, Net $ 10,707,027 $ 10,841,093 Depreciation expense for the three months ended September 30, 2018 and 2017 was $171,320 and $166,189, respectively.

Trademark and Patents

Trademark and Patents	3 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 - Trademark and Patents Trademark and patents, stated at cost, less accumulated amortization consisted of the following: September 30, 2018 June 30, 2018 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (86,094 ) (84,025 ) Trademarks and Patents, Net $ 372,860 $ 374,929 Amortization expense amounted to $2,069 and $2,068 for the three months ended September 30, 2018 and 2017, respectively.

Convertible Debenture and Deriv

Convertible Debenture and Derivatives	3 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 - Convertible Debenture and Derivatives Debenture - Series C The Company’s Series C Convertible Debenture, in the amount of $5,000,000, was redeemed on November 13, 2017. For the three month period ended September 30, 2017, the Holder of the Company’s Series C Convertible Debenture elected to receive $125,000 of their coupon interest payment and $41,667 of deferred interest payment in cash. The Company’s Series C Debenture in the amount of $5,000,000 was due to mature on June 30, 2018. On November 13, 2017, the Company entered into a Debenture Redemption Agreement (the “Agreement”) with the Holder, to redeem (the “Redemption”) its $5,000,000 Series C Convertible Debenture (the “Debenture”) for an aggregate of 5,500,000 shares of the Company’s $0.001 par value Common Stock (“Purchase Price”) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon interest from October 1, 2017 through June 30, 2018. The unpaid interest included $60,274 of accrued interest through November 13, 2017, $314,726 in coupon interest through June 30, 2018 and $125,000 of unpaid deferred interest. The price per share was equal to the closing price of the Company’s stock on Friday, November 10, 2017 of one ($1.00) dollar per share. The Holder waived all early redemption penalty payments provided for in the Debenture for consideration of 150,000 shares of the Company’s $0.001 par value Series A Convertible Preferred Stock. The Company did not incur placement agent fees in redemption of the Series C Convertible Debenture. The Company recognized a non-cash loss on extinguishment of debt of $1,348,247 on the extinguishment of the aforesaid principal attributable to the Series C Debentures into the Company’s common and preferred stock. The loss on extinguishment arises from, the obligation to issue 150,000 shares of the Company’s Series A Preferred shares with a fair value of $364,337, as of November 13, 2017, obligation to issue 314,726 shares of the Company’s $0.001 par value Common Stock with a fair value of $314,726 as of November 13, 2017, in consideration of Debenture coupon interest from the redemption date through June 30, 2018, and unamortized discount of $684,633 as of the redemption date, offset by the derivative liability of ($ 15,449 Pursuant to the redemption agreement for the Company’s Series C Debenture, the Company issued 5,500,000 shares of its registered Common Stock from its shelf registration and the 150,000 shares of its Series A Preferred Stock upon receiving consent to issue the shares pursuant to New York Stock Exchange (“NYSE”) regulations. The Company submitted a request for authorization to issue the Common Stock and Series A Preferred Shares to the NYSE, which was authorized on March 18, 2018 and the shares were issued on March 21, 2018. On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 shares of its Series A Convertible Preferred Stock (the “Series A”) to Dr. Milton Boniuk, pursuant to the terms of the Debenture. Proceeds received in a financing transaction are allocated to the instruments issued prior to evaluating hybrid contracts for bifurcation of embedded derivatives. Since the Series A Convertible Preferred Stock is classified as equity, the proceeds allocated to the Preferred Stock are recorded at relative fair value. The fair value of the Series A was $1,645,606 at issuance and the relative fair value was calculated as $1,152,297. The remaining amount of the proceeds was allocated to the Debenture and a debt discount of $1,152,297 was recorded to offset the amount of the proceeds allocated to the Series A. Then, the embedded derivative was bifurcated at its fair value of $1,879,428 with the remaining balance allocated to the host instrument (Debenture). The total debt discount was amortized over the actual term of the Debenture using the effective interest method. The Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amount of $ -0- and $239,351 for the three month periods ended September 30, 2018 and 2017, respectively.

Accrued expenses

Accrued expenses	3 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 8 – Accrued expenses Accrued expenses consisted of the following: September 30, 2018 June 30, 201 8 Severance payment- Eugene Seymour $ 133,333 $ 233,333 Accrued payroll 49,576 19,716 Professional Services 48,266 - Accrued Expenses $ 231,175 $ 253,049

Equity Transactions

Equity Transactions	3 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 - Equity Transactions On July 11, 2018 the Board of Directors approved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 525,000 of the Company’s Series A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June 30, 2021 and are subject to forfeiture. The Company recognized a non-cash compensation expense related to the issuance of the Series A Preferred stock of $47,260 for the three months ended September 30, 2018. The balance of $513,430 . For the three months ended September 30, 2018, the Company’s Board of Directors authorized the issuance of 7,716 fully vested shares of its Series A Convertible Preferred stock for employee compensation. The Company recorded an expense of $7,767. The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/11/2018 525,000 $ 560,690 7/31/2018 2,572 2,795 8/31/2018 2,572 2,374 9/30/2018 2,572 2,598 532,716 $ 568,457 There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred stock at each issuance used the following inputs: a. The common stock price was in the range $.42 to $.58; b. The calculated weighted average number of shares of common stock in the period; c. A 26.63 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years; f. 29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common. On July 19, 2018, the Company entered into an Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1, 2018. Dr. Taraporewala was granted options to purchase up to 300,000 shares of the Company’s common stock, par value $0.001 per share at an exercise price equal to 20% above the closing bid price of $0.41 was $35,761 of which $11,920 was recognized and recorded as compensation expense for the three months ended September 30, 2018. The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice simulation model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility. In August 2018, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 11,432 shares of common stock with an exercise price of $ .41 The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 55.12 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 2.71 % For the three months ended September 30, 2018, the Company’s Board of Directors authorized the issuance of 191,510 fully vested shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $79,460 for the three months, which was the fair value on the dates of issuance. For the three months ended September 30, 2018, the Company’s Board of Directors authorized the issuance of 19,310 of $7,500 issuance.

Stock Warrants and Options

Stock Warrants and Options	3 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 10 - Stock Warrants and Options Stock Warrants Stock Warrants Number of Weighted Weighted Aggregate Outstanding and exercisable at June 30, 2018 6,969,588 $ 4.80 .53 $ - Granted 11,432 .41 Expired 2,868,981 5.25 - Outstanding and exercisable at September 30, 2018 4,112,039 $ 4.48 .63 $ - Of the above warrants, 3,679,127 68,592 57,160 Stock Options Stock Options Number of Weighted Weighted Aggregate Outstanding at June 30, 2018 - $ - - $ - Granted 300,000 .50 - - Outstanding at September 30, 2018 300,000 .50 2.92 - Of the above options, 100,000 September 30, 2018, 100,000 . The Company estimated the fair value of the option grant at $35,761 and recognized the estimated value of the vested and exercisable options as a compensation expense of $11,920 for the three months ended September 30, 2018. The Company will recognize the remaining unrecognized fair value of the option grant of $23,841 in installments over the vesting period. The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility: Expected life (year) 3 Expected volatility 55.09 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 2.71 % Expected forfeiture (attrition) rate (%) 5.00 % Expected volatility is based on historical volatility of the Company’s common stock and the expected life of options. The Company estimates forfeitures at the time of valuation and reduces expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ or are expected to differ, from the previous estimate.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 11 - Fair Value Measurement Fair value measurements At September 30, 2018 and June 30, 2018 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at September 30, 2018: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ - $ - $ 122,541 Fair Value Measurements at June 30, 2018: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ - $ - $ 298,092 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014, the Company 5,425,363 warrants, of which 2,479,935 issued 135,216 76,306 of 2,556,241 offerings. The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of September 30, 2018 and June 30, 2018 with the following assumptions: - The 5-year warrants issued on 9/12/13 and 1/24/14 included Investor and Placement Agent Warrants with an exercise price of $5.25 and $6.05 (subject to adjustments-full ratchet reset). - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are: 1 Year 9/30/18 64 % 6/30/18 56 % The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018: Fair Value Measurement Fair Value Measurement Using Significant Unobservable Inputs Derivative Liability- Warrant Beginning balance at July 1, 2018 $ 298,092 Additions during the year - Change in fair value (175,551 ) Transfer in and out of Level 3 - Balance at September 30, 2018 $ 122,541

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 - Commitments and Contingencies Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of three years. Dr. Diwan’s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 525,000 shares of the Company’s Series A Preferred Stock. 175,000 shares vest equally on June 30, 2019, 2020 and 2021. Any unvested shares are subject to forfeiture. The Company and Dr. Irach Taraporewala, the Company’s Chief Executive Officer, entered into an employment agreement effective September 1, 2018, for a term of three years. Dr. Taraporewala will be paid an annual base salary of $360,000. Additionally, Dr. Taraporewala was awarded a grant of 300,000 options to purchase shares of the Company’s Common Stock. 100,000 options vested on September 1, 2018 and the remainder of the options will vest over the two year vesting period and are subject to forfeiture. On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $150,000. In addition, the Company issued 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock upon entering into the agreement, and issued an additional 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock on each anniversary date of the agreement. The shares of Series A Preferred Stock were issued in recognition of Dr. Tatake’s work towards the achievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements. On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $150,000. In addition, the Company issued 35,715 shares of common stock upon entering into the agreement, and issued an additional 35,715 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements. On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $9,000 per month and 2,572 shares of Series A Preferred Stock, also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The Agreement is renewable on an annual basis. The Compensation Committee of the Board of Directors has extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements. License Agreements The Company is dependent upon its license agreement with TheraCour (See Note 4).

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 13 - Subsequent Events On October 29, 2018, the Board of Directors of NanoViricides, Inc. (the “Company”) elected James Sapirstein as a new member of the Board. Mr. Sapirstein is an Independent Member of the Board of Directors and will serve as a member of the Company’s Audit, Compensation and Nominating Committees.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 13, 2018. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed on October 13, 2018.
Reclassification, Policy [Policy Text Block]	Reclassifications and Prior Year Adjustments Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. The Company reclassified $296,678 of expenses related to the Company’s laboratory facilities out of general and administrative expenses into research and development expenses for consistency with current year presentation. The reclassifications had no impact on the reported results of operations and net loss reported for the three months ended September 30, 2017.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2018 September 30, 2017 Options and Warrants 4,412,039 6,685,292 Total potentially outstanding dilutive common shares 4,412,039 6,685,292 At September 30, 2017, the number of potentially dilutive shares of the Company’s common stock into which the Series C debenture could be converted based upon the conversion provisions contained in the debenture was 952,381. The Series C debenture was redeemed for common stock effective November 13, 2017. The Company has also issued 5,064,110 shares of Series A Preferred Stock to investors and others as of September 30, 2018. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or the Company’s intellectual property. In the absence of a Change of Control event, the Series A convertible Preferred Stock is not convertible into common stock, and does not carry any dividend rights or any other financial effects. At September 30, 2018, the number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 17,724,385, and is not included in diluted earnings per share since the shares are contingently convertible only upon a Change of Control. The following represents the basic and diluted per share calculations for loss from continuing operations: For the three months ended 2018 2017 Calculation of basic and diluted loss per share of common stock: Net loss attributable to common stockholders $ (1,841,463 ) $ (2,005,555 ) Denominator for basic and diluted weighted average shares of common stock 69,185,965 63,307,083 Basic and diluted loss per share of common stock $ (0.03 ) $ (0.03 ) The Series C debenture was redeemed for Common Stock effective November 13, 2017. See Note 7. The Series C debenture was excluded from the loss per share calculation for the three-month period ended September 30, 2017 because the impact is anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In August 2018, the SEC issued the final rule on Disclosures About Changes in Stockholder’s Equity For filings on Form 10-Q, which extends to interim periods the annual requirement in SEC Regulation S-X, Rule 3-04,2 to disclose (1) changes in stockholders’ equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders’ equity, in the form of reconciliation, for “the current and comparative year-to-date [interim] periods, with subtotals for each interim period,” i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 permits the disclosure of changes in stockholders’ equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. The staff of the SEC has indicated it would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company expects to conform to this rule in its Form 10-Q for the quarter ending December 31, 2018. The Company believes that the final rule will not have a material effect on its consolidated financial statements and disclosures. In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact on its financial statements. In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Three Months Three Months Ended Ended September 30, 2018 September 30, 2017 Options and Warrants 4,412,039 6,685,292 Total potentially outstanding dilutive common shares 4,412,039 6,685,292 The following represents the basic and diluted per share calculations for loss from continuing operations: For the three months ended 2018 2017 Calculation of basic and diluted loss per share of common stock: Net loss attributable to common stockholders $ (1,841,463 ) $ (2,005,555 ) Denominator for basic and diluted weighted average shares of common stock 69,185,965 63,307,083 Basic and diluted loss per share of common stock $ (0.03 ) $ (0.03 )

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	As of September 30, 2018 June 30, 2018 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) to pay an advance payment equal to twice the amount of the previous month’ s invoice to be applied as a prepayment towards expenses. $ 718,457 $ 107,468 For the three months ended September 30, September 30, Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at September 30, 2018 and June 30, 2018. $ 846,688 $ 847,093

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: September 30, 2018 June 30, 2018 GMP Facility $ 8,020,471 $ 8,011,230 Land 260,000 260,000 Office Equipment 57,781 57,781 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,711,778 5,683,765 Total Property and Equipment 14,055,637 14,018,383 Less Accumulated Depreciation (3,348,610 ) (3,177,290 ) Property and Equipment, Net $ 10,707,027 $ 10,841,093

Trademark and Patents (Tables)

Trademark and Patents (Tables)	3 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: September 30, 2018 June 30, 2018 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (86,094 ) (84,025 ) Trademarks and Patents, Net $ 372,860 $ 374,929

Accrued expenses (Tables)

Accrued expenses (Tables)	3 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following: September 30, 2018 June 30, 201 8 Severance payment- Eugene Seymour $ 133,333 $ 233,333 Accrued payroll 49,576 19,716 Professional Services 48,266 - Accrued Expenses $ 231,175 $ 253,049

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Sep. 30, 2018
Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]	The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/11/2018 525,000 $ 560,690 7/31/2018 2,572 2,795 8/31/2018 2,572 2,374 9/30/2018 2,572 2,598 532,716 $ 568,457
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 55.12 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 2.71 %

Stock Warrants and Options (Tab

Stock Warrants and Options (Tables)	3 Months Ended
	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of the options granted to Dr. Taraporewala on the date of grant using a lattice model that values the options based upon a stock price modeled such that it follows a geometric Brownian motion with constant drift and volatility: Expected life (year) 3 Expected volatility 55.09 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 2.71 % Expected forfeiture (attrition) rate (%) 5.00 %
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Options Number of Weighted Weighted Aggregate Outstanding at June 30, 2018 - $ - - $ - Granted 300,000 .50 - - Outstanding at September 30, 2018 300,000 .50 2.92 -
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Warrants Number of Weighted Weighted Aggregate Outstanding and exercisable at June 30, 2018 6,969,588 $ 4.80 .53 $ - Granted 11,432 .41 Expired 2,868,981 5.25 - Outstanding and exercisable at September 30, 2018 4,112,039 $ 4.48 .63 $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At September 30, 2018 and June 30, 2018 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at September 30, 2018: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ - $ - $ 122,541 Fair Value Measurements at June 30, 2018: (Level 1) (Level 2) (Level 3) Derivative liability - warrants $ - $ - $ 298,092
Schedule Of Projected Annual Volatility [Table Text Block]	The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are: 1 Year 9/30/18 64 % 6/30/18 56 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended September 30, 2018: Fair Value Measurement Fair Value Measurement Using Significant Unobservable Inputs Derivative Liability- Warrant Beginning balance at July 1, 2018 $ 298,092 Additions during the year - Change in fair value (175,551 ) Transfer in and out of Level 3 - Balance at September 30, 2018 $ 122,541

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,412,039	6,685,292
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,412,039	6,685,292

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Calculation of basic and diluted loss per share of common stock:
Net loss attributable to common stockholders	$ (1,841,463)	$ (2,005,555)
Denominator for basic and diluted weighted average shares of common stock	69,185,965	63,307,083
Basic and diluted loss per share of common stock	$ (0.03)	$ (0.03)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Textual) - USD ($)	Nov. 13, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		4,412,039	6,685,292
Reclassification of General and Administrative Expenses into Research and Development Expenses			$ 296,678
Debt Conversion, Converted Instrument, Shares Issued	150,000
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		17,724,385
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 3.5
Convertible Preferred Stock, Terms of Conversion		60% or less
Preferred Stock, Shares Issued		5,064,110		4,531,394
Common Stock [Member] | Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			952,381

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Cash and Cash Equivalents, at Carrying Value	$ 6,082,365	$ 13,512,240	$ 7,081,771	$ 15,099,461
Retained Earnings (Accumulated Deficit)	(85,533,609)		$ (83,692,146)
Net Income (Loss) Attributable to Parent	(1,841,463)	(2,005,555)
Net Cash Provided by (Used in) Operating Activities	$ (962,152)	$ (1,556,788)

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018
Research and development	$ 1,411,483	$ 1,451,906
Theracour Pharma Inc [Member]
Net Account Payable to related party	718,457		$ 107,468
Research and development	$ 846,688	$ 847,093

Related Party Transactions (D_2

Related Party Transactions (Details Textual) - USD ($)	Oct. 02, 2018	Sep. 30, 2018	Sep. 30, 2017
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction		costs (direct and indirect) plus no more than 30% of direct costs
Other General and Administrative Expense		$ 2,000
Interest Expense, Debt			$ 5,000,000
Percentage Of Net Sales Allocated For Royalty Payments		15.00%
Research and Development Expense		$ 1,411,483	1,451,906
Theracour Pharma Inc [Member]
Related Party Transaction [Line Items]
Research and Development Expense		$ 846,688	847,093
Theracour Pharma Inc [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Research and Development Expense	$ 25,000
Series C Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt			$ 125,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Property, Plant and Equipment [Line Items]
GMP Facility	$ 8,020,471	$ 8,011,230
Land	260,000	260,000
Office Equipment	57,781	57,781
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,711,778	5,683,765
Total Property and Equipment	14,055,637	14,018,383
Less Accumulated Depreciation	(3,348,610)	(3,177,290)
Property and Equipment, Net	$ 10,707,027	$ 10,841,093

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation	$ 171,320	$ 166,189

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(86,094)	(84,025)
Trademarks and Patents, Net	$ 372,860	$ 374,929

Trademark and Patents (Details

Trademark and Patents (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Trademarks And Patents [Line Items]
Amortization	$ 2,069	$ 2,068
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 2,069	$ 2,068

Convertible Debenture and Der_2

Convertible Debenture and Derivatives (Details Textual) - USD ($)	Nov. 13, 2017	Jul. 02, 2014	Mar. 21, 2018	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jul. 19, 2018
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	150,000
Interest Expense, Debt					$ 5,000,000
Common Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues				$ 5,500,000
Share price as per Redemption Agreement				$ 1
Series Preferred Share Issued For Debenture Interest Shares Issued			150,000
Debt Conversion, Description	for an aggregate of 5,500,000 shares of the Company’s $0.001 par value Common Stock (“Purchase Price”) comprising 5,000,000 shares for the principal of the Debenture and 500,000 shares for unpaid coupon interest from October 1, 2017 through June 30, 2018.
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount				$ 684,633
Common Stock [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Value, New Issues				5,500,000
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)				$ 0	239,351
Debt Conversion, Converted Instrument, Shares Issued	150,000	187,000
Proceeds from Convertible Debt		$ 1,645,606
Repayments of Other Debt		1,152,297
Debt Instrument, Unamortized Discount		1,152,297
Debt Conversion, Converted Instrument, Amount		$ 1,879,428
Common Stock, Par or Stated Value Per Share	$ 0.001
Gain (Loss) on Extinguishment of Debt	$ 1,348,247
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 364,337
Stock Issued During Period, Shares, Other	314,726
Derivative Liability						$ 15,449
Stock Issued During Period, Value, Other	$ 314,726
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount						5,000,000
Interest Expense, Debt	314,726
Common Stock Value Issued For Debt Instrument Periodic Interest Payment					125,000	$ 125,000
Deferred Interest Payment					$ 41,667
Interest Payable, Current	60,274
Long-term Debt, Excluding Current Maturities	$ 5,000,000

Accrued expenses (Details)

Accrued expenses (Details) - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Severance payment- Eugene Seymour	$ 133,333	$ 233,333
Accrued payroll	49,576	19,716
Professional Services	48,266	0
Accrued Expenses	$ 231,175	$ 253,049

Equity Transactions (Details)

Equity Transactions (Details) - Series A Preferred Stock [Member]	3 Months Ended
	Sep. 30, 2018USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	532,716
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 568,457
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	525,000
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 560,690
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 2,795
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 2,374
Issuance Date Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 2,598

Equity Transactions (Details 1)

Equity Transactions (Details 1)	3 Months Ended
	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	4 years
Expected volatility	55.12%
Risk-free rate(s)	2.71%
Scientific Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual rate of quarterly dividends	0.00%

Equity Transactions (Details Te

Equity Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 19, 2018	Sep. 30, 2018	Sep. 30, 2017	Jul. 11, 2018	Jun. 30, 2018
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		7,716
Share-based Compensation		$ 11,920	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		55.12%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.71%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	300,000
Fair Value Measurement Significant Assumptions		a.The common stock price was in the range $.42 to $.58;b.The calculated weighted average number of shares of common stock in the period;c.A 26.63% premium over the common shares for the voting preferences;d.The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.22% to 19.25% of the total;e.The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 2.09 years;f.29.42% to 32.24% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 55.76% to 61.17% volatility, 2.09% to 2.11% risk free rate) applied to the converted common.
Share Price	$ 0.41	$ 0.42
Restricted Stock or Unit Expense		$ 7,767
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001			$ 0.001
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 35,761
Warrant [Member]
Class of Stock [Line Items]
Allocated Share-based Compensation Expense		$ 1,543
Warrant [Member] | August 2021
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		11,432
Warrant [Member] | February 2022 [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.41
Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		191,510
Share-based Compensation		$ 7,500
Restricted common stock authorized for interest payable		19,310
President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				525,000
Share-based Compensation		$ 47,260
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 513,430
Series A Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions		29.42%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		55.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.09%
Series A Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions		32.24%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		61.17%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.11%
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services		$ 79,460
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		26.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		4 years
Series A Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		19.22%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		2 years 1 month 2 days
Series A Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage		19.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		2 years 4 months 2 days
Share Price		$ 0.58

Stock Warrants and Options (Det

Stock Warrants and Options (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 19, 2018	Sep. 30, 2018	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	300,000
Weighted Average Exercise Price per share, Granted (dollars per share)		$ 0.50
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding			6,969,588
Number of Shares, Granted		11,432
Number of Shares, Expired		2,868,981
Number of Shares, Outstanding		4,112,039
Weighted Average Exercise Price per share, Outstanding (dollars per share)			$ 4.80
Weighted Average Exercise Price per share, Granted (dollars per share)		$ 0.41
Weighted Average Exercise Price per share, Expired (dollars per share)		5.25
Weighted Average Exercise Price per share, Outstanding (dollars per share)		$ 4.48
Weighted Average Remaining Contractual Term (years), Expired		0 years
Weighted Average Remaining Contractual Term (years), Outstanding		6 months 11 days	6 months 11 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 0	$ 0
Aggregate Intrinsic Value, Outstanding (in dollars)		$ 0	$ 0

Stock Warrants and Options (D_2

Stock Warrants and Options (Details 1) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 19, 2018	Sep. 30, 2018	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	300,000
Weighted Average Exercise Price per share, Granted (dollars per share)		$ 0.50
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding			0
Number of Shares, Granted		300,000
Number of Shares, Outstanding		300,000
Weighted Average Exercise Price per share, Outstanding (dollars per share)			$ 0
Weighted Average Exercise Price per share, Outstanding (dollars per share)		$ 0.50
Weighted Average Remaining Contractual Term (years), Granted		0 years
Weighted Average Remaining Contractual Term (years), Outstanding		2 years 11 months 1 day
Aggregate Intrinsic Value, Outstanding (in dollars)		$ 0	$ 0
Aggregate Intrinsic Value, Granted (in dollars)		$ 0

Stock Warrants and Options (D_3

Stock Warrants and Options (Details 2)	3 Months Ended
	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	4 years
Expected volatility	55.12%
Risk-free rate(s)	2.71%
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	3 years
Expected volatility	55.09%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	2.71%
Expected forfeiture (attrition) rate (%)	5.00%

Stock Warrants and Options (D_4

Stock Warrants and Options (Details Textual)	3 Months Ended
	Sep. 30, 2018USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $	$ 35,761
Stock or Unit Option Plan Expense | $	11,920
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $	$ 23,841
Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	100,000
Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	100,000
Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	100,000
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	3,679,127
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,592
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	57,160
June 30 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	45,728
June 30, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	261,432

Fair Value Measurement (Details

Fair Value Measurement (Details) - Warrant [Member] - USD ($)	Sep. 30, 2018	Jun. 30, 2018
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	$ 122,541	$ 298,092

Fair Value Measurement (Detai_2

Fair Value Measurement (Details 1)	3 Months Ended	12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018
One Year Ended 6/30/18
Fair Value Assumption Expected Volatility Rate		56.00%
One Year Ended 9/30/18
Fair Value Assumption Expected Volatility Rate	64.00%

Fair Value Measurement (Detai_3

Fair Value Measurement (Details 2) - Derivative liability - Warrants	3 Months Ended
	Sep. 30, 2018USD ($)
Beginning balance	$ 298,092
Additions during the year	0
Change in fair value	(175,551)
Transfer in and out of Level 3	0
Ending Balance	$ 122,541

Fair Value Measurement (Detai_4

Fair Value Measurement (Details Textual) - $ / shares	1 Months Ended		4 Months Ended
	Jan. 24, 2014	Sep. 12, 2013	Jan. 24, 2014	Sep. 30, 2018	Jun. 30, 2018
Class of Warrant or Right, Outstanding				2,479,935	5,290,006
Warrants Issued			5,425,363
Placement Agents [Member]
Class of Warrant or Right, Outstanding				76,306	135,216
Warrants Issued			135,216
Warrant Expiration Term	5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.05	$ 5.25	$ 6.05
Scientific Advisory Board [Member]
Class of Warrant or Right, Outstanding				2,556,241	5,425,222

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended			3 Months Ended
	Jan. 31, 2015	May 30, 2013	Mar. 03, 2010	Sep. 30, 2018	Jun. 30, 2018
Commitments and Contingencies [Line Items]
Common stock, shares issued				69,382,560	69,171,740
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 400,000
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance				525,000
Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				175,000
Share-based Compensation Award, Tranche Two [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				175,000
Share-based Compensation Award, Tranche Three [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				175,000
Chief Executive Officer [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 360,000
Chief Executive Officer [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				300,000
Chief Executive Officer [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 100,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued			35,715
Additional Common Stock Shares Issued			35,715
Increase In Base Salary			$ 150,000
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued			35,715
Additional Common Stock Shares Issued			35,715
Preferred stock, shares issued			26,786
Additional Preferred Stock Shares Issued			26,786
Increase In Base Salary			$ 150,000
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary	$ 10,800	$ 9,000
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued		2,572